North American Prodromal Synucleinopathy Consortium — NAPS  

Parkinson Disease Clinical Trial

Official title: North American Prodromal Synucleinopathy Consortium

Status Enrolling by invitation

Clinical Trial Summary

This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Clinical Trial Description

REM sleep behavior disorder (RBD) is a rare disorder where people act out their dreams. People with RBD often, but not always, develop Parkinson's Disease, dementia with Lewy bodies, multiple system atrophy, or other neurodegenerative diseases of the synucleinopathy type. The North American Prodromal Synucleinopathy (NAPS) Consortium was formed with the purpose of enrolling participants with RBD, in anticipation of a future clinical trial of a neuroprotective treatment against synucleinopathies. The NAPS Consortium will collect standardized clinical assessments, biofluids, and other data in order to develop biomarkers for synucleinopathies in the prodromal (presymptomatic) stage as well as a trial-ready registry of participants. Participants procedures will include a ~2-hour clinical assessment (medical history and physical exam), questionnaires, blood draw, and (at select sites) optional lumbar puncture. ;

Related Conditions & MeSH terms

• Atrophy
• Dementia
• Dementia With Lewy Bodies
• Lewy Body Disease
• Mental Disorders
• Multiple System Atrophy
• Parasomnias
• Parkinson Disease
• REM Sleep Behavior Disorder
• REM Sleep Parasomnias
• Shy-Drager Syndrome

• NCT number: NCT03623672
• Study type: Observational [Patient Registry]
• Source: Washington University School of Medicine
• Status: Enrolling by invitation
• Start date: August 29, 2018
• Completion date: July 31, 2022